Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 16;3(3):e259-e262.
doi: 10.1055/s-0039-1695710. eCollection 2019 Jul.

Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease

Renske H Olie  1   2 , Paola E J van der Meijden  1   2 , Henri M H Spronk  1 , Rene van Oerle  1 , Stale Barvik  3 , Vernon V S Bonarjee  3 , Hugo Ten Cate  1   2 , Dennis W T Nilsen  3
Affiliations

Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease

Renske H Olie et al. TH Open. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Dr. Olie reports nonfinancial support and other from MSD (Schering-Plough), Norway, during the conduct of the study. Dr. Nilsen reports grants from MSD (Schering-Plough), Norway, during the conduct of the study. All other authors reported no conflict of interest.

Figures

Fig. 1
Fig. 1
Results of soluble P-selectin, FIXa-AT, FXa-AT, and TAT complexes in vorapaxar-treated patients and placebo group. Compared with the placebo group, vorapaxar-treated patients had significantly lower levels of soluble P-selectin ( p  = 0.03) ( A ). No significant differences were found in factor IXa-antithrombin (FIXa-AT) ( B ), factor Xa-antithrombin (FXa-AT) ( C ), and thrombin–antithrombin (TAT) ( D ) complexes between vorapaxar-treated patients and the placebo group.
See this image and copyright information in PMC

References

    1. Morrow D A, Braunwald E, Bonaca M P et al.Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404–1413. - PubMed
    1. Chackalamannil S, Xia Y, Greenlee W J et al.Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J Med Chem. 2005;48(19):5884–5887. - PubMed
    1. Chackalamannil S. Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. J Med Chem. 2006;49(18):5389–5403. - PubMed
    1. Blann A D, Nadar S K, Lip G Y. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J. 2003;24(24):2166–2179. - PubMed
    1. Thomas M R, Storey R F. Effect of P2Y12 inhibitors on inflammation and immunity. Thromb Haemost. 2015;114(03):490–497. - PubMed